Selected Abstracts from Elevate-Derm Summer Conference 2025.

Introduction: Janus kinase inhibitors (JAKis)-developed to treat inflammatory and immune-mediated diseases-have shown an increased risk of acne development, especially when used to treat dermatologic conditions.There are no treatment guidelines for JAKiinduced acne.Some of the most efficacious treatments for acne vulgaris (AV) are triple combinations, including benzoyl peroxide (BPO), a topical retinoid, and an oral/topical antibiotic.Fixed-dose, triple-combination clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% (CAB) gel has demonstrated good efficacy, safety, and tolerability in Phase II and III clinical trials of participants with moderate-to-severe AV.This case report highlights the possible utility of once-daily CAB treatment for JAKiinduced acne.Methods: A 15-year-old female patient was administered the oral JAKi upadacitinib (15mg daily, titrated up to 30mg daily) for 16 weeks to treat atopic dermatitis (AD) that inadequately responded to 16 weeks of dupilumab treatment.The patient had mild, preexisting comedonal and inflammatory facial AV prior to JAKi treatment, which worsened over the first few months of JAKi treatment.By Week 16, the patient had moderate-to-severe inflammatory acne with erythema and postinflammatory hyperpigmentation.The patient applied CAB gel to the face once daily for approximately 20 weeks (without any other acne treatments) while continuing upadacitinib.Results: CAB treatment provided substantial improvements in acne without adverse effects.The patient's acne severity was reduced from moderate-to-severe to mild-to-almost clear, and there were no significant acneinduced sequelae (scarring, postinflammatory hyperpigmentation, or erythema).The patient continues treatment with both CAB and upadacitinib 15mg daily.Conclusion: JAKi treatment was highly effective in controlling the patient's AD when dupilumab could not, making successful acne treatment important for sustaining effective AD therapy.Treatment guidelines for AV and treatment recommendations for JAKi-induced acne often recommend oral drugs, such as isotretinoin, for moderate-to-severe acne.This case, however, demonstrates that topical CAB gel can treat moderate-to-severe JAKi-induced inflammatory acne.